News › Clinical Practice, Industry News, Patient Care

Allergan Receives FDA Approval for Juvéderm Voluma XC for Mid-face Injection via Cannula

September 11, 2019

Allergan plc has announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm Voluma XC, a hyaluronic acid gel dermal filler, with a TSK Steriglide cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm Voluma XC in the cheek area. The TSK Steriglide has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Misinformation on Hyaluronic Acid (HA) Fillers Taking Over Your Practice? A New Fact-Based Campaign by Allergan Aesthetics Sets the Story Straight
    • Hydrafacial Introduces HydraScalp with Keravive
    • CorralData Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Private Equity Bridgepoint Group Acquires Obagi Medical
    • Growth99 Introduces Gia: An AI Front Desk Built to Convert New Patient Inquiries Across Every Channel